World Health Organization site
Skip Navigation Links

Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Last refreshed on: 1 March 2021
Main ID:  NCT03496168
Date of registration: 05/04/2018
Prospective Registration: Yes
Primary sponsor: MyoKardia, Inc.
Public title: Extension Study of Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy Previously Enrolled in PIONEER PIONEER-OLE
Scientific title: An Open-Label Extension Study of Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy Previously Enrolled in Study MYK-461-004 (PIONEER)
Date of first enrolment: April 26, 2018
Target sample size: 12
Recruitment status: Active, not recruiting
Study type:  Interventional
Study design:  Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).  
Phase:  Phase 2
Countries of recruitment
United States
Name:     MyoKardia Medical Information Team
Affiliation:  MyoKardia, Inc.
Key inclusion & exclusion criteria

Key Inclusion Criteria:

- Completed Study MYK-461-004. Prior participation in a non-interventional observational
study is allowed.

- Body weight > 45 kg at Screening

- Has safety laboratory parameters (chemistry and hematology) within normal limits

Key Exclusion Criteria:

- Has QTcF > > 500 ms or any other ECG abnormality considered by the investigator to
pose a risk to subject safety (eg, second degree atrioventricular block type II)

- Since enrollment into Study MYK-461-004, has developed obstructive coronary artery
disease (> 70% stenosis in one or more arteries) or known moderate or severe aortic
valve stenosis

- Since enrollment into Study MYK-461-004, has developed any acute or serious comorbid
condition (eg, major infection or hematologic, renal, metabolic, gastrointestinal, or
endocrine dysfunction) that, in the opinion of the investigator or medical monitor,
would pose a risk to subject safety or interfere with the study evaluation,
procedures, or completion

- Since enrollment into Study MYK-461-004 has developed clinically significant malignant

Age minimum: 18 Years
Age maximum: N/A
Gender: All
Health Condition(s) or Problem(s) studied
Hypertrophic Cardiomyopathy
Drug: mavacamten
Primary Outcome(s)
Frequency and severity of adverse events and serious adverse events. [Time Frame: Up to 260 weeks]
Secondary Outcome(s)
Secondary ID(s)
Source(s) of Monetary Support
Please refer to primary and secondary sponsors
Secondary Sponsor(s)
Ethics review
Results available:
Date Posted:
Date Completed:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history